{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:18:36Z","timestamp":1790619516306,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    Rift Valley fever virus (RVFV) is a mosquito-borne bunyavirus that causes Rift Valley fever (RVF), a zoonotic disease of wild and domestic ruminants, causing serious economic losses and a threat to human health that could be controlled by vaccination. Though RVF vaccines are available for livestock, no RVF vaccines have been licensed for veterinary use in non-endemic countries nor for human populations in RVF risk areas. In a recent work, we showed that favipiravir, a promising drug with antiviral activity against a number of RNA viruses, led to the extinction of RVFV from infected cell cultures. Nevertheless, certain drug concentrations allowed the recovery of a virus variant showing increased resistance to favipiravir. In this work, we characterized this novel resistant variant both at genomic and phenotypic level\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Interestingly, the resistant virus displayed reduced growth rates in C6\/36 insect cells but not in mammalian cell lines, and was highly attenuated but still immunogenic\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Some amino acid substitutions were identified in the viral RNA-dependent RNA-polymerase (RdRp) gene and in the virus encoded type I-interferon (IFN-I) antagonist NSs gene, in catalytic core motifs and nuclear localization associated positions, respectively. These data may help to characterize novel potential virulence markers, offering additional strategies for further safety improvements of RVF live attenuated vaccine candidates.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2020.621463","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T02:37:39Z","timestamp":1612838259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers"],"prefix":"10.3389","volume":"11","author":[{"given":"Bel\u00e9n","family":"Borrego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e00487","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J. Virol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1040841X.2017.1307805","article-title":"Bunyaviridae RdRps: structure, motifs, and RNA synthesis machinery","volume":"43","author":"Amroun","year":"2017","journal-title":"Crit. Rev. Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e03679","DOI":"10.7554\/eLife.03679.021","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"Arias","year":"2014","journal-title":"Elife"},{"key":"B4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2217\/fvl.15.31","article-title":"Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines","volume":"10","author":"Baker","year":"2015","journal-title":"Future Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","article-title":"NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription","volume":"78","author":"Billecocq","year":"2004","journal-title":"J. Virol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007","journal-title":"J. Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.16.342170","article-title":"A hyper-attenuated variant of Rift Valley fever virus (RVFV) generated by a mutagenic drug (favipiravir) unveils potential virulence markers","author":"Borrego","year":"2020","journal-title":"bioRxiv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e00669","DOI":"10.1128\/AAC.00669-19","article-title":"Lethal mutagenesis of rift valley fever virus induced by favipiravir","volume":"63","author":"Borrego","year":"2019","journal-title":"Antimicrob. Agents Chemother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2021010439","DOI":"10.20944\/preprints202101.0439.v1","article-title":"The change P82L in the Rift Valley fever virus NSs protein confers attenuation in mice not related with a type-I IFN antagonistic phenotype","author":"Borrego","year":"2021","journal-title":"Preprints"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1128\/JVI.02641-10","article-title":"Rift valley fever: recent insights into pathogenesis and prevention","volume":"85","author":"Boshra","year":"2011","journal-title":"J. Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J. Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.virol.2013.07.030","article-title":"Viruses of the family Bunyaviridae: are all available isolates reassortants?","volume":"446","author":"Briese","year":"2013","journal-title":"Virology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1038\/ncomms5794","article-title":"Generation and characterization of influenza A viruses with altered polymerase fidelity","volume":"5","author":"Cheung","year":"2014","journal-title":"Nat. Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16038","DOI":"10.1073\/pnas.1111650108","article-title":"Arbovirus high fidelity variant loses fitness in mosquitoes and mice","volume":"108","author":"Coffey","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J. Antimicrob. Chemother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018","journal-title":"Curr. Opin. Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e01400","DOI":"10.1128\/AAC.01400-17","article-title":"Extinction of west nile virus by favipiravir through lethal mutagenesis","volume":"61","author":"Escribano-Romero","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.virusres.2017.01.018","article-title":"Transcription and replication mechanisms of bunyaviridae and arenaviridae L proteins","volume":"234","author":"Ferron","year":"2017","journal-title":"Virus Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.cell.2015.05.006","article-title":"Structural insights into bunyavirus replication and its regulation by the vRNA promoter","volume":"161","author":"Gerlach","year":"2015","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1421","DOI":"10.1371\/journal.pntd.0001421","article-title":"Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice","volume":"5","author":"Gommet","year":"2011","journal-title":"PLoS Negl. Trop. Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin. Biol. Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L Segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J. Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0139001","DOI":"10.1371\/journal.pone.0139001","article-title":"Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications","volume":"10","author":"Jacome","year":"2015","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/emi.2014.71","article-title":"The Rift Valley fever accessory proteins NSm and P78\/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts","volume":"3","author":"Kreher","year":"2014","journal-title":"Emerg. Microbes Infect"},{"key":"B29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat. Biotech"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0004550","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PLoS Negl. Trop. Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4161\/mabs.2.3.11676","article-title":"Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization","volume":"2","author":"Martin-Folgar","year":"2010","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1099\/0022-1317-75-6-1345","article-title":"Rift valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases","volume":"75","author":"Muller","year":"1994","journal-title":"J Gen Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"B34","first-page":"895","article-title":"Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull. World Health Organ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e00081","DOI":"10.1128\/JVI.00081-17","article-title":"Attenuation of foot-and-mouth disease virus by engineered viral polymerase fidelity","volume":"91","author":"Rai","year":"2017","journal-title":"J. Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1038\/emi.2013.81","article-title":"The risk of Rift Valley fever virus introduction and establishment in the United States and European Union","volume":"2","author":"Rolin","year":"2013","journal-title":"Emerg. Microbes Infect"},{"key":"B37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3181\/00379727-64-15803","article-title":"Human infection with Rift Valley fever virus and immunity twelve years after single attack","volume":"64","author":"Sabin","year":"1947","journal-title":"Proc. Soc. Exp. Biol. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8196","DOI":"10.1128\/JVI.73.10.8196-8200.1999","article-title":"Genetic reassortment of Rift Valley fever virus in nature","volume":"73","author":"Sall","year":"1999","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3390\/v7072808","article-title":"Using the hepatitis C virus RNA-dependent RNA polymerase as a model to understand viral polymerase structure, function and dynamics","volume":"7","author":"Sesmero","year":"2015","journal-title":"Viruses"},{"key":"B40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nm1726","article-title":"Engineering attenuated virus vaccines by controlling replication fidelity","volume":"14","author":"Vignuzzi","year":"2008","journal-title":"Nat. Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31618","DOI":"10.1074\/jbc.C112.401471","article-title":"A Polymerase mechanism-based strategy for viral attenuation and vaccine development","volume":"287","author":"Weeks","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e87385","DOI":"10.1371\/journal.pone.0087385","article-title":"Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6\/36 cells","volume":"9","author":"Weingartl","year":"2014","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s00705-014-2126-z","article-title":"Foot-and-mouth disease virus low-fidelity polymerase mutants are attenuated","volume":"159","author":"Xie","year":"2014","journal-title":"Arch. Virol"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2020.621463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T02:37:43Z","timestamp":1612838263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2020.621463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":43,"alternative-id":["10.3389\/fmicb.2020.621463"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2020.621463","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.16.342170","asserted-by":"object"}]},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"article-number":"621463"}}